HTL Biotechnology Secures Medical Device Registration in China

HTL Biotechnology Completes Registration for “Sodium DNA Raw Material Main Document” (Polynucleotides) as a Medical Device, Leading the Chinese Market with Pharmaceutical-Grade Biopolymer Technology and Services

Recently, HTL Biotechnology completed the registration of the “Sodium DNA Raw Material Main Document” (Polynucleotides) as a medical device (number M2024199-000) in China.

This marks an important milestone for the company in advancing within the Chinese medical device market and pursuing global medical innovation. This achievement, following HTL Biotechnology’s acquisition of a recombinant protein platform (including rhCOL3) further establishes HTL Biotechnology as a global player in the pharmaceutical and biopolymer fields.

Polynucleotides as unique biopolymers, exhibit vast potential in fields such as medical aesthetics, wound repair, and tissue regeneration, owing to its unique repair and regeneration capabilities. Used in injectable medical devices, polynucleotides have regenerative anti-ageing and anti-inflammatory properties. They can also be added to cosmetic formulations to create regenerative cosmetic products.

As a major global supplier of low and high molecular weight polynucleotides, HTL Biotechnology has unique advantages in producing polynucleotide raw materials: HTL Biotechnology’s polynucleotides are produced from deep-sea wild salmon milt, which is reused as a co-product of sustainably fished wild salmon. Its manufacturing process preserves the original DNA structure with a extremely high level of purity and enables a wide range of molecular weights.

HTL Biotechnology operates two state-of-the-art production units for polynucleotides in France, efficiently meeting all customer demands and ensuring an uninterrupted supply chain. Additionally, the company is developing a new production area to further enhance productivity and accommodate the growing market needs.